MSG Rangers Corp Class A (MSGR) Fund Overview
MSG Rangers Corp Class A (MSGR) — price $254.55 (+2.14%), as of the Nov 20, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
MSG Rangers Corp Class A · MSGR · NYSE
Direxion mRNA ETF (MSGR) aims to track the performance of companies leading the development and application of messenger RNA (mRNA) technology. The fund invests primarily in publicly listed companies in the United States, Canada, and Europe.
Price as of Nov 20, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $254.55 |
| Change on the day | +2.14% |
| 52-week range | $176.00 – $254.55 |
| Shares traded on the day | 226.9K |
Price & events
What is MSG Rangers Corp Class A (MSGR), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MSG Rangers Corp Class A (MSGR) is listed on NYSE. It employs 147 people and is led by James L. Dolan. In Q1 FY2026 it reported revenue of $14M and net income of -$17M.
What do the latest results show for MSG Rangers Corp Class A (MSGR)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $14M.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $14M | -$17M | -$1.40 (diluted) |
What are the financial strengths and risks for MSG Rangers Corp Class A (MSGR)?
Short answer · as of
Trailing ratios: ROA -4.2% · current ratio 0.52 · earnings yield -0.9% · free-cash-flow yield -2.2%.
What should you watch next at MSG Rangers Corp Class A (MSGR)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $352.15M · EPS -3.91 · 3 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No Altman Z or Piotroski screen is held for this filer.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $352.15M
- EPS estimate
- $-3.91
Measured against a quoted price of $254.55 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MSGR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MSGR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
MSG Rangers Corp Class A Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the MSGR research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What do analysts say about MSGR stock?
However, the fund's performance is closely tied to the overall sentiment and growth prospects of the mRNA technology sector. Investors should monitor industry news, clinical trial results, and regulatory developments to assess the potential risks and rewards associated with MSGR.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com